Clinical trial NCT02462213 - References

Cardiomyopathies — Prospective Identification of Cardiac Amyloidosis by Cardiac Magnetic Resonance Imaging

Citation(s)

•   Buxbaum JN
  The systemic amyloidoses. Curr Opin Rheumatol. 2004 Jan;16(1):67-75. Review.
•   Dispenzieri A, Lacy MQ, Katzmann JA, Rajkumar SV, Abraham RS, Hayman SR, Kumar SK, Clark R, Kyle RA, Litzow MR, Inwards DJ, Ansell SM, Micallef IM, Porrata LF, Elliott MA, Johnston PB, Greipp PR, Witzig TE, Zeldenrust SR, Russell SJ, Gastineau D, Gertz MA
  Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2006 Apr 15;107(8):3378-83. Epub 2006 Jan 5.
•   Dubrey SW, Cha K, Anderson J, Chamarthi B, Reisinger J, Skinner M, Falk RH
  The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM. 1998 Feb;91(2):141-57.
•   Falk RH
  Diagnosis and management of the cardiac amyloidoses. Circulation. 2005 Sep 27;112(13):2047-60. Review.
•   Guglin M, Aljayeh M, Saiyad S, Ali R, Curtis AB
  Introducing a new entity: chemotherapy-induced arrhythmia. Europace. 2009 Dec;11(12):1579-86. doi: 10.1093/europace/eup300. Epub 2009 Oct 3. Review.
•   Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, Bundy J, Finn JP, Klocke FJ, Judd RM
  Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999 Nov 9;100(19):1992-2002.
•   Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, Klocke FJ, Bonow RO, Judd RM
  The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000 Nov 16;343(20):1445-53.
•   Klein AL, Cohen GI
  Doppler echocardiographic assessment of constrictive pericarditis, cardiac amyloidosis, and cardiac tamponade. Cleve Clin J Med. 1992 May-Jun;59(3):278-90. Review.
•   Krombach GA, Hahn C, Tomars M, Buecker A, Grawe A, Günther RW, Kühl HP
  Cardiac amyloidosis: MR imaging findings and T1 quantification, comparison with control subjects. J Magn Reson Imaging. 2007 Jun;25(6):1283-7.
•   Kyle RA, Gertz MA
  Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995 Jan;32(1):45-59.
•   Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, Sheppard MN, Poole-Wilson PA, Hawkins PN, Pennell DJ
  Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005 Jan 18;111(2):186-93. Epub 2005 Jan 3.
•   Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ
  Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson. 2008 Nov 25;10:54. doi: 10.1186/1532-429X-10-54.
•   McCrohon JA, Moon JC, Prasad SK, McKenna WJ, Lorenz CH, Coats AJ, Pennell DJ
  Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation. 2003 Jul 8;108(1):54-9. Epub 2003 Jun 23.
•   Merlini G, Bellotti V
  Molecular mechanisms of amyloidosis. N Engl J Med. 2003 Aug 7;349(6):583-96. Review.
•   Noordzij W, Glaudemans AW, van Rheenen RW, Hazenberg BP, Tio RA, Dierckx RA, Slart RH
  (123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis. Eur J Nucl Med Mol Imaging. 2012 Oct;39(10):1609-17. Epub 2012 Jul 18.
•   Shah KB, Inoue Y, Mehra MR
  Amyloidosis and the heart: a comprehensive review. Arch Intern Med. 2006 Sep 25;166(17):1805-13. Review.
•   Shakir DK, Rasul KI
  Chemotherapy induced cardiomyopathy: pathogenesis, monitoring and management. J Clin Med Res. 2009 Apr;1(1):8-12. doi: 10.4021/jocmr2009.02.1225. Epub 2009 Mar 24.
•   Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards WD, Gertz MA, Dispenzieri A, Oh JK, Bellavia D, Tajik AJ, Grogan M
  Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging. 2010 Feb;3(2):155-64. doi: 10.1016/j.jcmg.2009.09.023.
•   vanden Driesen RI, Slaughter RE, Strugnell WE
  MR findings in cardiac amyloidosis. AJR Am J Roentgenol. 2006 Jun;186(6):1682-5.

The Influence of Amyloid Protein on Myocardial Tissue Characteristics and Function: Prognostic and Diagnostic Significance of Cardiac Magnetic Resonance Findings

Details for clinical trial NCT02462213